Bicheng Wang

26PUBLICATIONS
8CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jan 14, 2026
Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma.

Bi-Cheng Wang

|Dec 18, 2025
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.

Jing Tang, Yongqiang Yang, Dongen Liu

|Jul 23, 2025
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk et al.

Bi-Cheng Wang

|Apr 30, 2025
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer.

Bi-Cheng Wang

|Mar 21, 2025
Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.

Bi-Cheng Wang

|Feb 06, 2025
Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer-a prospective observation study.

Bi-Cheng Wang

Pageof 5

Frequent Collaborators

1 joint publications

Canliang Lu

1 joint publications

Jing Tang

1 joint publications

Yongqiang Yang

1 joint publications

Dongen Liu